Status:
COMPLETED
High-amylose Barley (HIAMBA) in the Regulation and Prevention of Type 2 Diabetes
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Innovation Fund Denmark
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In a series of double-blinded randomized cross-over acute studies, the investigators want to study the effects of naturally produced high-amylose barley (Lean-baking barley®) on the postprandial gluco...
Detailed Description
The prevalence of T2D is increasing worldwide, primarily due to obesity, lack of physical activity and unhealthy diet. Therefore, it is of great important to evolve dietary products that counteracts t...
Eligibility Criteria
Inclusion
- Inclusion Criteria for T2D group:
- T2D defined by standard Danish guidelines.
- HbA1c between 42-78 mmol/l.
- Treatment with drugs for hypertension and high cholesterol is allowed if the treatment dose is stable and does not demand changes during the study period.
- Participants are encouraged to maintain their present psychical activity level and their smoking and alcohol habits.
- Exclusion Criteria:
- Type 1 diabetes
- Insulin demanding T2D
- Use of weekly administrated GLP-1 antagonist (e.g. ozempic, trulicity or byetta)
- Use of acarbose
- Significant cardiovascular, kidney, liver or endocrine comorbidity
- Significant psychiatric history
- Treatment with steroids
- Alcohol or drug abuse
- Pregnancy or breastfeeding
- Legally incompetent
Exclusion
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2024
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT04702672
Start Date
January 1 2023
End Date
July 31 2024
Last Update
November 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8200